Background/Objective: The prevalence of selected psychiatric disorders, such as depression and anxiety, is higher in patients with psoriasis. However, the association between psoriasis and schizophrenia is less clear. Here, we investigated whether the prevalence of schizophrenia is higher in patients with psoriasis. Methods: In this cross-sectional study, we analyzed the 1-million-person cohort enrolled from Taiwan's National Health Insurance Research Database. Psoriasis, schizophrenia, and comorbidities were ascertained by the International Classification of Diseases, 9 th revision, Clinical Modification coding. For schizophrenia, the concomitant catastrophic illness certificate was used to verify the diagnosis. The prevalence of schizophrenia in patients with psoriasis was compared with the prevalence of schizophrenia in a comparable population using a generalized linear mixed model. Results: The prevalence of schizophrenia was significantly higher in patients with psoriasis than in the comparison population [prevalence ratio ¼ 1.77, 95% confidence interval (CI) ¼ 1.48e2.12, p < 0.0001)]. Within the psoriasis cohort, patients aged between 40 years and 59 years had a higher odds ratio (OR) for schizophrenia (OR ¼ 2.49, 95% CI ¼ 1.55e4.00, p ¼ 0.0002). Furthermore, psoriatic patients with comorbid cerebrovascular disease (OR ¼ 2.01, 95% CI ¼ 1.11e3.65, p ¼ 0.0220) and chronic pulmonary disease (OR ¼ 1.64, 95% CI ¼ 1.07e2.49, p ¼ 0.0218) had higher odds for schizophrenia. Conclusion: Schizophrenia is more prevalent in patients with psoriasis. Although the exact mechanisms remain to be clarified, the finding that psoriatic patients with comorbid cerebrovascular disease or chronic pulmonary disease have higher odds for schizophrenia may imply psoriatic patients with those comorbidities are likely to have higher inflammatory burden, which would contribute to the development of schizophrenia if a disruption of the bloodebrain barrier is present. Further investigations are indicated to validate the hypothesis explaining the association between known comorbidies of psoriasis and schizophrenia.
Introduction
Psoriasis is a chronic inflammatory disease affecting the skin and joints. 1 The itch and pain caused by the skin and joint lesions affect patient quality of life. 2e4 Moreover, the appearance of skin lesions often have negative impacts on patient psychological and social functions. 5, 6 A growing body of literature indicates that psychiatric disorders are more prevalent in patients with psoriasis. 7e9 In psoriatic patients, the prevalence of depression is estimated to be 15.4%. 10 Another study reported that pediatric patients with psoriasis have higher risks of developing depression and anxiety. 7 The higher prevalence of depression and anxiety in psoriatic patients may be attributed to discomforts caused by inflammation and discomfiture caused by visible skin lesions. The association between psoriasis and schizophrenia has not been well-established. A study reported that psoriatic patients are Conflicts of interest: The authors declare that they have no financial or nonfinancial conflicts of interest related to the subject matter or materials discussed in this article.more likely to receive antidepressants and anxiolytics, but not antipsychotics. 7 However, Chen et al 11 indicated that the odds ratio (OR) of psoriasis is 1.60 in male patients with schizophrenia, while the OR of psoriasis is not significantly higher in female patients with schizophrenia. Another nationwide population-based study conducted in Taiwan showed female patients, but not male patients, with schizophrenia have increased risk of psoriasis. 12 Given these conflicting results, the association between psoriasis and schizophrenia remains to be clarified.
Methods

Data source
The Taiwan government launched the compulsory National Health Insurance (NHI) program in 1995, with~98% of Taiwanese residents now enrolled in the NHI program. Medical records, including patient-demographic characteristics, diagnoses, healthcare utilization, and expenses, are included in the NHI program. The International Classification of Diseases, 9 th revision, Clinical Modification (ICD-9-CM) is used to record diagnoses in the NHI program. To ensure the reliability of ICD-9-CM coding in the NHI program, the Bureau of Taiwan performed random checking and imposed fines for false claims. The NHI Research Database (NHIRD) includes claim data from the NHI program. The NHIRD ensures enrollee confidentiality through assigning an anonymous code to each enrollee. The accuracy of ICD-9-CM coding in the NHIRD was previously validated. 13, 14 NHIRD is further classified into several data subsets for different research purposes. In this study, we used the "Longitudinal Health Insurance Database 2010" (LHID 2010), which is a NHIRD data subset containing longitudinal data of 1,000,000 enrollees randomly sampled from 2010. This study was approved by the Institutional Review Board of the Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Study population
We analyzed the 1-million-person cohort enrolled in the LHID 2010 database and excluded people < 20-years old (born after January 1, 1990 ) and people > 100-years old (born before January 1, 1910). The study cohort (psoriatic patients) was composed of enrollees diagnosed with psoriasis or psoriatic arthritis during the period from January 1, 1997 to December 31, 2010 , while the population comparisons (nonpsoriatic patients) consisted of enrollees who had not been diagnosed with psoriasis or psoriatic arthritis during the study period. Patient ascertainment was determined based on the ICD-9-CM codes. Patients with psoriasis were defined as enrollees documented with ICD-9-CM codes 696.0, 696.1, or 696.8 one or more times during the study period. These codes have been used in psoriasis studies using the NHIRD. 15e17 We identified 10,796 psoriatic patients and 767,327 individuals for the comparison population. Additionally, age-group and sex-matched comparisons were further allocated to psoriatic patients with a ratio of 1:1. Figure 1 shows the algorithm associated with study population selection.
Construction of variables
The primary outcome of our interest was schizophrenia. Patients with schizophrenia were defined as enrollees documented with ICD-9-CM code 295 one time or more and held a catastrophic illness certificate due to schizophrenia during the study period. Certification of catastrophic illness is strict in Taiwan, and catastrophic illnesses are defined by the Department of Health and Welfare of the Taiwan Government. If a patient is diagnosed with a disease classified as a catastrophic illness by at least one specialist, the patient can submit supporting documents to apply for a catastrophic illness certificate. Once approved, the catastrophic illness of the patient will be registered by the NHI program, and the patient can waive copayment for related conditions for future inpatient and outpatient care.
Covariates included age, sex, and comorbidities. Age was stratified into three age groups, including 20e39 years, 40e59 years, and 60 years. Each comorbidity was ascertained by ICD-9-CM codes documented over three times during the study period.
The ICD-9-CM codes for each comorbidity have been adopted in previous studies.
14,18
Statistical analysis
In this cross-sectional study, prevalence of schizophrenia and 95% confidence interval (CI) in psoriatic patients and the comparison Figure 1 Algorithm of study population selection.
population were estimated by a generalized linear mixed model and assuming a Poisson distribution. The prevalence ratio (PR) was calculated and compared between psoriatic patients and the comparison population by using a log-binomial model. Within psoriatic patients, the crude and adjusted ORs of factors were calculated using a multiple logistic regression model. For univariate analysis, c 2 and t tests were used for categorical and continuous variables, respectively.
We used the Joinpoint Regression Program (version 4.2.0.2; National Cancer Institute, Bethesda, MD, USA; http://surveillance. cancer.gov/joinpoint/) to estimate trends in the prevalence of schizophrenia in psoriatic patients and the comparison population. The Joinpoint Regression Program is statistical software used for the analysis of trends using joinpoint models. The annual percent change indicates the magnitude of the trend for each time period. We used the Joinpoint program to estimate trends in the prevalence of schizophrenia in each calendar year from 2000 to 2010.
Results
Characteristics of psoriatic patients and the comparison population
Characteristics of the study population are shown in Table 1 . There were 10,796 patients who met the inclusion criteria of psoriasis. The comparison population was composed of 767,327 people, with significant differences in age and gender between psoriatic patients and the comparison population. Comorbidities, including myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic pulmonary disease, rheumatologic disease, liver disease, diabetes, hemiplegia or paraplegia, and renal disease, were significantly more common in psoriatic patients than in the comparison population.
Prevalence of schizophrenia in psoriatic patients and the comparison population
The prevalence of schizophrenia was significantly higher in psoriatic patients than in the comparison population ( Table 2 ). The prevalence ratio was 1.77 (95% CI ¼ 1.48e2.12, p < 0.0001). When further stratified by age group, psoriatic patients > 40-years old exhibited significantly higher prevalence of schizophrenia than members of the comparison group. The prevalence ratio was significantly higher in both males (prevalence ratio ¼ 1.59, 95% CI ¼ 1.24e2.04, p ¼ 0.0003) and females (prevalence ratio ¼ 1.99, 95% CI ¼ 1.54e2.58, p 0.0001). When further stratified by comorbidities, psoriatic patients with cerebrovascular disease, chronic pulmonary disease, and liver disease exhibited a higher prevalence of schizophrenia as compared with the comparison group. In the age-group and sex-matched model, psoriatic patients also showed higher adjusted OR of schizophrenia (OR ¼ 1.44, 95% CI ¼ 1.08e1.92, p ¼ 0.0122) as compared with controls (Table S1 ).
ORs of factors for schizophrenia in psoriatic patients
Within the psoriatic cohort, patients aged between 40 years and 59 years exhibited higher adjusted OR (OR ¼ 2.49, 95% CI ¼ 1.55e4.00, p ¼ 0.0002) for schizophrenia (Table 3 ). There was no statistically significant difference in risk of schizophrenia between male and female psoriatic patients. The adjusted ORs of psoriatic patients with cerebrovascular disease and chronic pulmonary disease were 2.01 (95% CI (Table 4 ). The AAPC of schizophrenia was significantly higher in the psoriatic group as compared with that observed in the comparison population (AAPC difference ¼ 9.6, 95% CI ¼ 3.9e15.4, p < 0.05).
Discussion
While previous research showed conflicting results regarding associations between schizophrenia and psoriasis, 7, 11, 12 our study showed that the prevalence of schizophrenia is higher in both male and female psoriatic patients. The prevalence ratios were significantly higher in psoriatic patients > 40-years old and in psoriatic patients with comorbidities, including cerebrovascular disease, chronic pulmonary disease, and liver disease. Within psoriatic patients, older age, cerebrovascular disease, and chronic pulmonary disease exhibited higher odds for schizophrenia. Although the trends of schizophrenia increased in both the psoriatic cohort and the general population from 2000 to 2010 ( Figure 2 and Table 4 ), the trend in the psoriatic cohort was significantly higher (AAPC difference ¼ 9.6, p < 0.05).
Psoriasis is a chronic immune-mediated disease involving systemic inflammation.
19e21 T helper 17 (Th17) cells and proinflammatory cytokines, such as tumor necrosis factor-a, play a crucial role in the microenvironment of psoriasis. 19 Th17 cells and proinflammatory cytokines are also involved in the pathogenesis of schizophrenia. 22e24 Activation of Th17 cells occurs in patients with drug-naive, first-episode schizophrenia. 25 Given that psoriatic patients with cerebrovascular disease exhibit increased ORs for The reason that psoriatic patients with chronic pulmonary disease exhibit increased ORs relative to those without chronic pulmonary disease remains to be clarified. It is possible that psoriatic patients with comorbid lung disease have a dysregulated immune response that is involved in both psoriasis and schizophrenia. Additionally, methotrexate use may increase the risk of lung diseases.
26e28 It is possible that psoriatic patients with chronic pulmonary disease reflected those with severe psoriasis and receiving methotrexate treatment. Whether methotrexate use in psoriatic patients is associated with the higher prevalence is unclear. Further study is needed to elucidate potential associations between methotrexate use, psoriasis, and schizophrenia. Notably, in psoriatic patients, the presentation of schizophrenia is more prevalent in women and those aged > 40-years. Generally, schizophrenia is more common in men than in women, with a ratio of 1.4:1, and women tend to experience disease onset in older age. 29 In women, there is a peak occurrence between the ages of 20 years and 35 years, with a second smaller peak between the ages of 45 years and 49 years. 30 Estrogen exhibits a neuroprotective role and may account for the sex difference in schizophrenia. 31 Interestingly, it was also proposed that estrogen might improve psoriasis by inhibiting T cell response and reducing cytokine and chemokine secretion by keratinocytes. 32 Considering the protective roles of estrogen in both schizophrenia and psoriasis, decreased estrogen levels may contribute to the onset of schizophrenia in female psoriatic patients susceptible to schizophrenia in older age. 29, 33 Further investigations are required to test this hypothesis.
There were some limitations to this study. First, this is a crosssectional study; therefore, the causal relationship between psoriasis and schizophrenia could not be determined. Second, the identification of patients relied upon ICD-9-CM codes from the claim database. Psoriatic patients were defined as enrollees that had been documented with a code of psoriasis one time or more during the study period. However, there may be mismatches between coding and diagnosis. For schizophrenia, the possibility of miscoding was reduced by using concomitant catastrophic illness certificates to define schizophrenia. Third, we only adjusted for age, gender, and comorbidities in the statistical analysis. Psoriasis and schizophrenia are complex diseases, and some confounding factors may not be included in our analysis. 34, 35 Medication use, for example, could be involved in the association between psoriasis and schizophrenia. The role of medication was not evaluated in our present study.
In conclusion, the prevalence of schizophrenia is higher in male and female patients with psoriasis. Psoriatic patients with comorbid cerebrovascular disease or chronic pulmonary disease have higher ORs for schizophrenia as compared with psoriatic patients without these diseases. Although the exact mechanisms remain to be clarified, psoriatic patients having cerebrovascular disease or chronic pulmonary disease are likely to have higher disease activity, and, therefore, higher inflammatory burden. These factors may contribute to the development of schizophrenia if a disruption of the bloodebrain barrier is present. Decreased estrogen levels may also play a role in the link between psoriasis and schizophrenia. 
